Format

Send to

Choose Destination
Drugs Today (Barc). 2011 Jul;47(7):515-29. doi: 10.1358/dot.2011.47.7.1608922.

Velaglucerase alfa: a new option for Gaucher disease treatment.

Author information

1
Shaare Zedek Medical Center, Jerusalem, Israel. azimran@gmail.com

Abstract

Type 1 Gaucher disease (GD) results from inherited β-glucocerebrosidase gene mutations, leading to anemia, thrombocytopenia, splenomegaly, hepatomegaly and skeletal disease. Velaglucerase alfa is a β-glucocerebrosidase produced by gene activation in a human cell line, and indicated for type 1 GD. A phase I/II clinical trial (TKT025; N = 12), its ongoing extension (TKT025EXT) and three phase III trials (total N = 82), showed that velaglucerase alfa is generally well tolerated in adult and pediatric patients. Many disease-related parameters improved significantly in two phase III trials in treatment-naïve patients, and were successfully maintained in imiglucerase-experienced patients in a phase II/III switch study. Ten adults in TKT025EXT sustained improvements through 5 years, including bone mineral density. Comparison with imiglucerase shows that velaglucerase alfa is an effective, generally well-tolerated alternative enzyme replacement therapy. In vitro data suggest velaglucerase alfa may be internalized into cells more efficiently and have a lower rate of seroconversion. However, these results do not necessarily correlate with clinical efficacy.

PMID:
22013559
DOI:
10.1358/dot.2011.47.7.1608922
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clarivate Analytics
Loading ...
Support Center